Pharmacokinetics of intravenous amiodarone in children

Sergej Ramusovic, Stephanie Läer, Bernd Meibohm, Florian B. Lagler, Thomas Paul

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives: Although amiodarone is an effective treatment for severe paediatric arrhythmias, uncertainties about adverse effects such as hypotension, bradycardia and excessive serum drug concentrations persist. Therefore, the aims of this study were to: (a) determine serum concentrations of intravenous (IV) amiodarone following a widely implemented dosing regimen of 5 mg/kg bolus plus a 10 mg/kg/day continuous infusion and (b) generate descriptive data on safety parameters such as hypotension, bradycardia or corrected QT (QTc) prolongation during this regimen. Design: Prospective observational study. Setting: Paediatric intensive care unit. Patients: Twenty paediatric patients (median age, 0.23 years; range, 6 days-15.04 years) with arrhythmia secondary to or without cardiac surgery. Interventions: None. Main outcome measures: Amiodarone serum concentrations, blood pressure, heart rate, QTc intervals. Results: Amiodarone serum concentrations increased markedly during bolus, followed by rapid decreases during maintenance infusion. All patients had serum concentrations regarded as effective in adults (median concentration range: 1.30-2.06 μM/L during maintenance phase). Amiodarone suppressed arrhythmias in 18 (90%) patients. Mean QTc intervals for pretherapy, during and post-therapy periods were 443 ms, 458 ms and 467 ms, respectively. Eight patients had hypotension. Conclusions: Amiodarone was effective in the majority of children in this small cohort.

Original languageEnglish (US)
Pages (from-to)989-993
Number of pages5
JournalArchives of Disease in Childhood
Volume98
Issue number12
DOIs
StatePublished - Dec 1 2013

Fingerprint

Amiodarone
Pharmacokinetics
Hypotension
Cardiac Arrhythmias
Serum
Bradycardia
Maintenance
Pediatrics
Pediatric Intensive Care Units
Thoracic Surgery
Uncertainty
Observational Studies
Heart Rate
Outcome Assessment (Health Care)
Prospective Studies
Blood Pressure
Safety
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Pharmacokinetics of intravenous amiodarone in children. / Ramusovic, Sergej; Läer, Stephanie; Meibohm, Bernd; Lagler, Florian B.; Paul, Thomas.

In: Archives of Disease in Childhood, Vol. 98, No. 12, 01.12.2013, p. 989-993.

Research output: Contribution to journalArticle

Ramusovic, Sergej ; Läer, Stephanie ; Meibohm, Bernd ; Lagler, Florian B. ; Paul, Thomas. / Pharmacokinetics of intravenous amiodarone in children. In: Archives of Disease in Childhood. 2013 ; Vol. 98, No. 12. pp. 989-993.
@article{f3fa70128c2f49b99a2470877c29e731,
title = "Pharmacokinetics of intravenous amiodarone in children",
abstract = "Objectives: Although amiodarone is an effective treatment for severe paediatric arrhythmias, uncertainties about adverse effects such as hypotension, bradycardia and excessive serum drug concentrations persist. Therefore, the aims of this study were to: (a) determine serum concentrations of intravenous (IV) amiodarone following a widely implemented dosing regimen of 5 mg/kg bolus plus a 10 mg/kg/day continuous infusion and (b) generate descriptive data on safety parameters such as hypotension, bradycardia or corrected QT (QTc) prolongation during this regimen. Design: Prospective observational study. Setting: Paediatric intensive care unit. Patients: Twenty paediatric patients (median age, 0.23 years; range, 6 days-15.04 years) with arrhythmia secondary to or without cardiac surgery. Interventions: None. Main outcome measures: Amiodarone serum concentrations, blood pressure, heart rate, QTc intervals. Results: Amiodarone serum concentrations increased markedly during bolus, followed by rapid decreases during maintenance infusion. All patients had serum concentrations regarded as effective in adults (median concentration range: 1.30-2.06 μM/L during maintenance phase). Amiodarone suppressed arrhythmias in 18 (90{\%}) patients. Mean QTc intervals for pretherapy, during and post-therapy periods were 443 ms, 458 ms and 467 ms, respectively. Eight patients had hypotension. Conclusions: Amiodarone was effective in the majority of children in this small cohort.",
author = "Sergej Ramusovic and Stephanie L{\"a}er and Bernd Meibohm and Lagler, {Florian B.} and Thomas Paul",
year = "2013",
month = "12",
day = "1",
doi = "10.1136/archdischild-2013-304483",
language = "English (US)",
volume = "98",
pages = "989--993",
journal = "Archives of Disease in Childhood",
issn = "0003-9888",
publisher = "BMJ Publishing Group",
number = "12",

}

TY - JOUR

T1 - Pharmacokinetics of intravenous amiodarone in children

AU - Ramusovic, Sergej

AU - Läer, Stephanie

AU - Meibohm, Bernd

AU - Lagler, Florian B.

AU - Paul, Thomas

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Objectives: Although amiodarone is an effective treatment for severe paediatric arrhythmias, uncertainties about adverse effects such as hypotension, bradycardia and excessive serum drug concentrations persist. Therefore, the aims of this study were to: (a) determine serum concentrations of intravenous (IV) amiodarone following a widely implemented dosing regimen of 5 mg/kg bolus plus a 10 mg/kg/day continuous infusion and (b) generate descriptive data on safety parameters such as hypotension, bradycardia or corrected QT (QTc) prolongation during this regimen. Design: Prospective observational study. Setting: Paediatric intensive care unit. Patients: Twenty paediatric patients (median age, 0.23 years; range, 6 days-15.04 years) with arrhythmia secondary to or without cardiac surgery. Interventions: None. Main outcome measures: Amiodarone serum concentrations, blood pressure, heart rate, QTc intervals. Results: Amiodarone serum concentrations increased markedly during bolus, followed by rapid decreases during maintenance infusion. All patients had serum concentrations regarded as effective in adults (median concentration range: 1.30-2.06 μM/L during maintenance phase). Amiodarone suppressed arrhythmias in 18 (90%) patients. Mean QTc intervals for pretherapy, during and post-therapy periods were 443 ms, 458 ms and 467 ms, respectively. Eight patients had hypotension. Conclusions: Amiodarone was effective in the majority of children in this small cohort.

AB - Objectives: Although amiodarone is an effective treatment for severe paediatric arrhythmias, uncertainties about adverse effects such as hypotension, bradycardia and excessive serum drug concentrations persist. Therefore, the aims of this study were to: (a) determine serum concentrations of intravenous (IV) amiodarone following a widely implemented dosing regimen of 5 mg/kg bolus plus a 10 mg/kg/day continuous infusion and (b) generate descriptive data on safety parameters such as hypotension, bradycardia or corrected QT (QTc) prolongation during this regimen. Design: Prospective observational study. Setting: Paediatric intensive care unit. Patients: Twenty paediatric patients (median age, 0.23 years; range, 6 days-15.04 years) with arrhythmia secondary to or without cardiac surgery. Interventions: None. Main outcome measures: Amiodarone serum concentrations, blood pressure, heart rate, QTc intervals. Results: Amiodarone serum concentrations increased markedly during bolus, followed by rapid decreases during maintenance infusion. All patients had serum concentrations regarded as effective in adults (median concentration range: 1.30-2.06 μM/L during maintenance phase). Amiodarone suppressed arrhythmias in 18 (90%) patients. Mean QTc intervals for pretherapy, during and post-therapy periods were 443 ms, 458 ms and 467 ms, respectively. Eight patients had hypotension. Conclusions: Amiodarone was effective in the majority of children in this small cohort.

UR - http://www.scopus.com/inward/record.url?scp=84888639702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888639702&partnerID=8YFLogxK

U2 - 10.1136/archdischild-2013-304483

DO - 10.1136/archdischild-2013-304483

M3 - Article

VL - 98

SP - 989

EP - 993

JO - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

SN - 0003-9888

IS - 12

ER -